Table 4.

Stratification analysis on CYP19A1 and CYP1A2 polymorphisms and T2DM risk

SNP	Subgroups	Co-dominant (HOM)		Co-dominant (HET)		Dominant		Recessive		Additive		Allele
		OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
CYP19A1
rs4646	Age (≤ 59)	2.01(1.03–3.94)	0.041*	0.91(0.63–1.33)	0.633	1.05(0.73–1.50)	0.789	2.10(1.10–4.02)	0.026*	1.19(0.90–1.56)	0.226	1.20(0.92–1.58)	0.185
rs6493487	Age (≤ 59)	1.96(0.98–3.91)	0.055	0.86(0.59–1.26)	0.442	1.00(0.70–1.43)	0.997	2.09(1.07–4.08)	0.032*	1.14(0.87–1.51)	0.345	1.17(0.88–1.55)	0.280
rs1062033	Age (≤ 59)	0.93(0.55–1.57)	0.783	0.50(0.33–0.75)	0.001*	0.59(0.40–0.87)	0.008*	1.41(0.89–2.23)	0.149	0.88(0.68–1.14)	0.333	0.88(0.68–1.13)	0.319
rs17601876	Age (≤ 59)	1.79(0.94–3.40)	0.076	0.93(0.64–1.35)	0.690	1.04(0.73–1.49)	0.818	1.86(1.01–3.43)	0.048*	1.16(0.89–1.53)	0.275	1.17(0.89–1.53)	0.254
rs3751599	Diabetic retinopathy	–	–	0.53(0.27–1.04)	0.064	0.51(0.26–0.98)	0.045*	–	–	0.50(0.26–0.95)	0.034*	0.53(0.29–0.99)	0.044*
CYP1A2
rs762551	Age (> 59)	0.63(0.36–1.10)	0.106	1.21(0.82–1.78)	0.344	1.06(0.73–1.54)	0.771	0.55(0.33–0.92)	0.023*	0.87(0.67–1.13)	0.299	0.88(0.69–1.12)	0.290
	BMI (≤ 24)	0.32(0.14–0.74)	0.006*	1.07(0.62–1.86)	0.799	0.81(0.49–1.36)	0.424	0.31(0.14–0.66)	0.002*	0.67(0.46–0.96)	0.031*	0.70(0.49–1.00)	0.047*
rs2470890	Disease course (> 9)	–	–	0.54(0.31–0.95)	0.033*	0.61(0.35–1.06)	0.077	–	–	0.72(0.43–1.20)	0.208	0.77(0.48–1.25)	0.290

SNP single nucleotide polymorphism, OR odds ratio, 95% CI 95% confidence interval, HOM homozygous, HET heterozygous, BMI body mass index

“-” indicates no results

P value was calculated by logistic regression analysis with adjustment for age and gender

*P < 0.05 indicates statistical significance